Jaguar Health, Inc.
crofelemer
rare intestinal failure diseases
Date
TBD
FDA decision · Date TBD estimated
What's at stake
The FDA's approval decision on crofelemer for rare intestinal failure diseases is due Date TBD. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 13h ago
“the Company for our crofelemer-based prescription drug candidate for rare intestinal failure diseases.”